Related Experiment Video
Updated: Aug 5, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
Published on: August 20, 2019
Advances in Functional Genomics for Human Health
1Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Functional genomics helps understand genetic variations in the "dark matter" of the genome. This approach clarifies the clinical significance of intergenic abnormalities for human health.
Area of Science:
- Genetics
- Genomics
- Molecular Biology
Background:
- Cytogenomic assays like karyotyping and FISH have identified genetic abnormalities linked to various clinical phenotypes.
- However, many detected abnormalities in intergenic regions lack clear clinical significance, often termed the genome's
- dark matter
- .
Purpose of the Study:
- To review the application of functional genomics in understanding the clinical implications of intergenic genomic abnormalities.
- To highlight how functional genomics can elucidate the role of non-coding DNA in human health.
Main Methods:
- Review of existing literature on functional genomics and cytogenomic findings.
- Focus on studies investigating intergenic abnormalities and their impact on gene regulation and disease.
Main Results:
- Functional genomics can robustly explore the clinical implications of intergenic abnormalities.
- Examples include diseases like preaxial polydactyly (SHH gene), Pierre Robin syndrome (SOX9), and 5q14.3 microdeletion syndrome (MEF2C).
- Functional genomics aids in understanding disruptions to topologically associating domains (TADs) and regulatory regions.
Conclusions:
- Functional genomics offers a powerful approach to decipher the clinical significance of genetic variations in previously uncharacterized genomic regions.
- Leveraging functional genomics in intergenic regions is crucial for advancing human health and diagnosing genetic disorders.
More Related Videos
11:35Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)
Published on: August 21, 2016
03:08Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
Published on: October 3, 2025
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Genomics
Pharmacogenetics and Pharmacogenomics: Overview
Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...